BACKGROUND: Hypertriglyceridemia is a risk factor for cardiovascular disease. Variation in the apolipoprotein A5 (APOA5) and glucokinase regulatory protein (GCKR) genes has been associated with fasting plasma triacylglycerol. OBJECTIVE: We investigated the combined effects of the GCKR rs780094C-->T, APOA5 -1131T-->C, and APOA5 56C-->G single nucleotide polymorphisms (SNPs) on fasting triacylglycerol in several independent populations and the response to a high-fat meal and fenofibrate interventions. DESIGN: We used a cross-sectional design to investigate the association with fasting triacylglycerol in 8 populations from America, Asia, and Europe (n = 7,730 men and women) and 2 intervention studies in US whites (n = 1,061) to examine postprandial triacylglycerol after a high-fat meal and the response to fenofibrate. We defined 3 combined genotype groups: 1) protective (homozygous for the wild-type allele for all 3 SNPs); 2) intermediate (any mixed genotype not included in groups 1 and 3); and 3) risk (carriers of the variant alleles at both genes). RESULTS: Subjects within the risk group had significantly higher fasting triacylglycerol and a higher prevalence of hypertriglyceridemia than did subjects in the protective group across all populations. Moreover, subjects in the risk group had a greater postprandial triacylglycerol response to a high-fat meal and greater fenofibrate-induced reduction of fasting triacylglycerol than did the other groups, especially among persons with hypertriglyceridemia. Subjects with the intermediate genotype had intermediate values (P for trend <0.001). CONCLUSIONS: SNPs in GCKR and APOA5 have an additive effect on both fasting and postprandial triacylglycerol and contribute to the interindividual variability in response to fenofibrate treatment.
BACKGROUND:Hypertriglyceridemia is a risk factor for cardiovascular disease. Variation in the apolipoprotein A5 (APOA5) and glucokinase regulatory protein (GCKR) genes has been associated with fasting plasma triacylglycerol. OBJECTIVE: We investigated the combined effects of the GCKR rs780094C-->T, APOA5 -1131T-->C, and APOA5 56C-->G single nucleotide polymorphisms (SNPs) on fasting triacylglycerol in several independent populations and the response to a high-fat meal and fenofibrate interventions. DESIGN: We used a cross-sectional design to investigate the association with fasting triacylglycerol in 8 populations from America, Asia, and Europe (n = 7,730 men and women) and 2 intervention studies in US whites (n = 1,061) to examine postprandial triacylglycerol after a high-fat meal and the response to fenofibrate. We defined 3 combined genotype groups: 1) protective (homozygous for the wild-type allele for all 3 SNPs); 2) intermediate (any mixed genotype not included in groups 1 and 3); and 3) risk (carriers of the variant alleles at both genes). RESULTS: Subjects within the risk group had significantly higher fasting triacylglycerol and a higher prevalence of hypertriglyceridemia than did subjects in the protective group across all populations. Moreover, subjects in the risk group had a greater postprandial triacylglycerol response to a high-fat meal and greater fenofibrate-induced reduction of fasting triacylglycerol than did the other groups, especially among persons with hypertriglyceridemia. Subjects with the intermediate genotype had intermediate values (P for trend <0.001). CONCLUSIONS: SNPs in GCKR and APOA5 have an additive effect on both fasting and postprandial triacylglycerol and contribute to the interindividual variability in response to fenofibrate treatment.
Authors: E D Slosberg; U J Desai; B Fanelli; I St Denny; S Connelly; M Kaleko; B R Boettcher; S L Caplan Journal: Diabetes Date: 2001-08 Impact factor: 9.461
Authors: L Qi; D Corella; J V Sorlí; O Portolés; H Shen; O Coltell; D Godoy; A S Greenberg; J M Ordovas Journal: Clin Genet Date: 2004-10 Impact factor: 4.438
Authors: Michael Y Tsai; Angeliki Georgopoulos; James D Otvos; Jose M Ordovas; Naomi Q Hanson; James M Peacock; Donna K Arnett Journal: Clin Chem Date: 2004-05-13 Impact factor: 8.327
Authors: Ariel Brautbar; Daniel Covarrubias; John Belmont; Fremiet Lara-Garduno; Salim S Virani; Peter H Jones; Suzanne M Leal; Christie M Ballantyne Journal: Atherosclerosis Date: 2011-08-22 Impact factor: 5.162
Authors: Carmen Sánchez-Moreno; Jose M Ordovás; Caren E Smith; Juan C Baraza; Yu-Chi Lee; Marta Garaulet Journal: J Nutr Date: 2011-01-05 Impact factor: 4.798
Authors: L Maria Belalcazar; George D Papandonatos; Bahar Erar; Inga Peter; Hadeel Alkofide; Ashok Balasubramanyam; Ariel Brautbar; Steven E Kahn; William C Knowler; Christie M Ballantyne; Jeanne M McCaffery; Gordon S Huggins Journal: Circ Cardiovasc Genet Date: 2015-11-17
Authors: Mark Bi; Wen Hong Linda Kao; Eric Boerwinkle; Ron C Hoogeveen; Laura J Rasmussen-Torvik; Brad C Astor; Kari E North; Josef Coresh; Anna Köttgen Journal: PLoS One Date: 2010-07-22 Impact factor: 3.240
Authors: Pablo Perez-Martinez; Juan F Alcala-Diaz; Edmon K Kabagambe; Antonio Garcia-Rios; Michael Y Tsai; Javier Delgado-Lista; Genovefa Kolovou; Robert J Straka; Francisco Gomez-Delgado; Paul N Hopkins; Carmen Marin; Ingrid Borecki; Elena M Yubero-Serrano; James E Hixson; Antonio Camargo; Michael A Province; Javier Lopez-Moreno; Fernando Rodriguez-Cantalejo; Francisco J Tinahones; Dimitri P Mikhailidis; Francisco Perez-Jimenez; Donna K Arnett; Jose M Ordovas; Jose Lopez-Miranda Journal: J Clin Lipidol Date: 2016-06-01 Impact factor: 4.766
Authors: Haiqing Shen; Toni I Pollin; Coleen M Damcott; John C McLenithan; Braxton D Mitchell; Alan R Shuldiner Journal: Hum Genet Date: 2009-06-13 Impact factor: 4.132